BMO Capital Markets Cuts Silence Therapeutics (NASDAQ:SLN) Price Target to $25.00

Silence Therapeutics (NASDAQ:SLN) had its target price reduced by research analysts at BMO Capital Markets from $67.00 to $25.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. BMO Capital Markets’ price target would suggest a potential upside of 447.05% from the company’s current price.

A number of other research analysts also recently issued reports on the company. Chardan Capital reaffirmed a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Wednesday, January 29th. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Finally, The Goldman Sachs Group cut their price objective on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Silence Therapeutics Stock Up 5.8 %

Shares of NASDAQ:SLN traded up $0.25 on Tuesday, hitting $4.57. 65,035 shares of the company traded hands, compared to its average volume of 315,461. Silence Therapeutics has a 52 week low of $4.06 and a 52 week high of $27.72. The company has a market cap of $136.78 million, a PE ratio of -2.91 and a beta of 1.05. The stock has a 50 day simple moving average of $5.58 and a 200-day simple moving average of $11.65.

Institutional Trading of Silence Therapeutics

A number of large investors have recently made changes to their positions in the stock. Woodline Partners LP raised its holdings in shares of Silence Therapeutics by 22.6% in the fourth quarter. Woodline Partners LP now owns 498,732 shares of the company’s stock valued at $3,431,000 after acquiring an additional 91,829 shares in the last quarter. Two Sigma Advisers LP raised its holdings in shares of Silence Therapeutics by 18.6% in the fourth quarter. Two Sigma Advisers LP now owns 98,800 shares of the company’s stock worth $680,000 after buying an additional 15,500 shares during the last quarter. Redmile Group LLC raised its holdings in shares of Silence Therapeutics by 26.3% during the fourth quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock worth $16,507,000 after purchasing an additional 500,000 shares during the last quarter. Point72 Asset Management L.P. grew its stake in shares of Silence Therapeutics by 35.3% during the 4th quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company’s stock worth $4,356,000 after purchasing an additional 165,300 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Silence Therapeutics by 50.5% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 128,990 shares of the company’s stock worth $887,000 after purchasing an additional 43,289 shares during the period. 98.73% of the stock is owned by hedge funds and other institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.